Rational engineering of human cytochrome P450 2B6 for enhanced expression and stability: Importance of a Leu264→Phe substitution

Molecular Pharmacology

Volumn 72, Issue 5, 2007, Pages 1191-1199

  Kumar, Santosh ^a   Zhao, Yonghong ^b   Sun, Ling ^a   Negi, Surendra S ^a   Halpert, James R ^a   Muralidhara, B K ^c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b CENTOCOR INC   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZPHETAMINE; CYTOCHROME P450 2B6; IMIDAZOLE DERIVATIVE; PYRIDINE;

ARTICLE; CONTROLLED STUDY; DENATURATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME STABILITY; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SUBSTITUTION; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME STABILITY; ESCHERICHIA COLI; GROEL PROTEIN; GROES PROTEIN; HEAT; HUMANS; LEUCINE; MOLECULAR CHAPERONES; MUTATION; PHENYLALANINE; PROTEIN CONFORMATION; PROTEIN ENGINEERING; SUBSTRATE SPECIFICITY; THERMODYNAMICS;

EID: 35548933849     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.039693     Document Type: Article

References (40)

1. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, and Waxman DJ (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
2. Domanski TL and Halpert JR (2001) Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Metab 2:117-137.
3. Eijsink VG, Bjork A, Gaseidnes S, Sirevag R, Synstad B, van den Burg B, and Vriend G (2004) Rational engineering of enzyme stability. J Biotechnol 113:105-120.
4. Fraczkiewicz R and Braun W (1998) Exact and efficient analytical calculation of the accessible surface area and their gradient for macromolecules. J Comput Chem 19:319-333.
5. Guengerich FP (2005) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed. (Ortiz de Montellano PR ed) p 377-530, Plenum Press, New York.
6. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of putative substrate recognition sites in human cytochrome P4503A4. J Biol Chem 272:5396-5402.
7. Joerger AC, Allen MD, and Fersht AR (2004) Crystal structure of a superstable mutant of human p53 core domain: insights into the mechanism of rescuing oncogenic mutations. J Biol Chem 279:1291-1296.
8. Josephy D and Logan D (2007) Whole cell assay for spectroscopic measurement of recombinant cytochrome P450 expression in bacteria. Varian, Inc., Palo Alto, CA. http://www.varianinc.com/cgi-bin/nav?applications/apps/ uv86&cid=HFIH.
9. Kent UM, Pascual L, Roof RA, Ballou DP, and Hollenberg PF (2004) Mechanistic studies with N-benzyl-1-aminobenzotriazole-inactivated CYP2B1: Differential effects on the metabolism of 7-ethoxy-4-(trifluoromethyl)coumarin, testosterone, and benzphetamine. Arch Biochem Biophys 423:277-287.
10. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, and Brockmoller J (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-626.
11. Kumar S, Chen CS, Waxman DJ, and Halpert JR (2005) Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide. J Biol Chem 280:19569-19575.
12. Kumar S, Sun L, Liu H, Muralidhara BK, and Halpert JR (2006a) Engineering mammalian cytochrome P450 2B1 by directed evolution for enhanced catalytic tolerance to temperature and dimethyl sulfoxide. Protein Eng Des Select 34:1958-1965.
13. Kumar S, Liu H, and Halpert JR (2006b) Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab Dispos 34:1958-1965.
14. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
15. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, Schwab M, and Zanger UM (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311:34-43.
16. Lawson RJ, Leys D, Sutcliffe MJ, Kemp CA, Cheesman MR, Smith SJ, Clarkson J, Smith WE, Haq I, Perkins JB, et al. (2004) Thermodynamic and biophysical characterization of cytochrome P450 BioI from Bacillus subtilis. Biochemistry 43:12410-12426.
17. Lehmann M, Loch C, Middendorf A, Studer D, Lassen SF, Pasamontes L, van Loon AP, and Wyss M (2002) The consensus concept for thermostability engineering of proteins: further proof of concept. Protein Eng 15:403-411.
18. Lewis DF, Lake BG, and Dickins M (2004) Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism. Drug Metab Drug Interact 20:111-142.
19. Mitsuda M and Iwasaki M (2006) Improvement in the expression of CYP2B6 by co-expression with molecular chaperones GroES/EL in E. coli. Protein Expr Purif 46:401-405.
20. Muralidhara BK and Halpert JR (2007) Thermodynamics of ligand binding to P450 2B4 and P450eryF studied by isothermal titration calorimetry. Drug Metab Rev, in press.
21. Muralidhara BK, Negi S, Chin CC, Braun W, and Halpert JR (2006) Conformational flexibility of mammalian cytochrome P4502B4 in binding imidazole inhibitors with different ring chemistry and side chains - solution thermodynamics and molecular modeling. J Biol Chem 281:8051-8061.
22. Muralidhara BK, Negi S, and Halpert JR (2007) Dissecting the thermodynamics and cooperativity of ligand binding in cytochrome P450eryF. J Am Chem Soc 129: 2015-2024.
23. Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, and Aoyama T (1994) Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem Res Toxicol 7:891-896.
24. Nikolova PV, Henckel J, Lane DP, and Fersht AR (1998) Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A 95:14675-14680.
25. Nishida CR and Ortiz de Montellano PR (2005) Thermophilic cytochrome P450 enzymes. Biochem Biophys Res Commun 338:437-445.
26. Patel SB, Cameron PM, Frantz-Wattley B, O'Neill E, Becker JW, and Scapin G (2004) Lattice stabilization and enhanced diffraction in human p38 alpha crystals by protein engineering. Biochim Biophys Acta 1696:67-73.
27. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
28. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Décosterd L, Blievernicht J, Saussele T, Günthard HF, Schwab M, Eichelbaum M, Telenti A, and Zanger UM. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 81:557-566.
29. Schlatter D, Thoma R, Kung E, Stihle M, Muller F, Borroni E, Cesura A, and Hennig M (2005) Crystal engineering yields crystals of cyclophilin D diffracting to 1.7 Å resolution. Acta Crystallogr D Biol Crystallogr 61:513-519.
30. Scott EE, He YA, Wester MR, White MA, Chin CC, Halpert JR, Johnson EF, and Stout CD (2003) An open conformation of mammalian cytochrome P450 2B4 at 1.6 Å resolution. Proc Natl Acad Sci U S A 100:13196-13201.
31. Scott EE, Spatzenegger M, Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 395:57-68.
32. Scott EE, White MA, He YA, Johnson EF, Stout CD, and Halpert JR (2004) Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9 Å resolution: insight into the range of P450 conformations and the coordination of redox partner binding. J Biol Chem 279:27294-27301.
33. Thomas JH (2007) Rapid birth-death evolution specific to xenobiotic cytochrome P450 genes in vertebrates. PLoS Genetics 3:720-728.
34. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306: 287-300.
35. Watanabe K, Ohkuri T, Yokobori S, and Yamagishi A (2006) Designing thermostable proteins: ancestral mutants of 3-isopropylmalate dehydrogenase designed by using a phylogenetic tree. J Mol Biol 355:664-674.
36. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, and Rane A (2003) Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3:53-61.
37. Yano JK, Blasco F, Li H, Schmid RD, Henne A, and Poulos TL (2003) Preliminary characterization and crystal structure of a thermostable cytochrome P450 from Thermus thermophilus. J Biol Chem 278:608-616.
38. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann M, and Schwab M (2007) Polymorphic CYP2B6: molecular mechanism and emerging clinical significance. Pharmacogenomics 8:743-759.
39. Zhao Y, White MA, Muralidhara BK, Sun L, Halpert JR, and Stout CD (2006) Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction. J Biol Chem 281:5973-5981.
40. Zhao YH and Halpert JR (2007) Structure-function analysis of P450 2B. Biochem Biophys Acta 1770:402-412.